0001209191-21-022205.txt : 20210319 0001209191-21-022205.hdr.sgml : 20210319 20210319210026 ACCESSION NUMBER: 0001209191-21-022205 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210318 FILED AS OF DATE: 20210319 DATE AS OF CHANGE: 20210319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Palaniappan Jyoti CENTRAL INDEX KEY: 0001807021 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21759639 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVENUE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-18 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001807021 Palaniappan Jyoti C/O ADAPTIVE BIOTECHNOLOGIES CORP. 1551 EASTLAKE AVE E STE 200 SEATTLE WA 98102 0 1 0 0 SVP, Diagnostics, immunoSEQ Dx Common Stock 2021-03-18 4 M 0 16052 22.55 A 25210 D Common Stock 2021-03-18 4 S 0 8342 43.04 D 16868 D Common Stock 2021-03-18 4 S 0 5971 43.83 D 10897 D Common Stock 2021-03-18 4 S 0 1739 45.32 D 9158 D Stock Option (Right to Buy) 22.55 2021-03-18 4 M 0 16052 0.00 D 2030-03-19 Common Stock 16052 108948 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.60 to 43.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.63 to 44.53, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.63 to 45.54, inclusive. The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Jyoti Palaniappan by Eric Billings as attorney-in-fact 2021-03-19